Cargando…

Bendamustine in patients with relapsed or refractory multiple myeloma

OBJECTIVE: In patients with multiple myeloma, bendamustine monotherapy is effective as 1(st )and 2(nd )line therapy. However, data for patients with advanced multiple myeloma is rare. METHODS: In this retrospective analysis we have identified 39 patients with relapsed or refractory multiple myeloma...

Descripción completa

Detalles Bibliográficos
Autores principales: Michael, M, Bruns, I, Bölke, E, Zohren, F, Czibere, A, Safaian, N N, Neumann, F, Haas, R, Kobbe, G, Fenk, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351842/
https://www.ncbi.nlm.nih.gov/pubmed/20159666
http://dx.doi.org/10.1186/2047-783X-15-1-13
_version_ 1782232806668107776
author Michael, M
Bruns, I
Bölke, E
Zohren, F
Czibere, A
Safaian, N N
Neumann, F
Haas, R
Kobbe, G
Fenk, R
author_facet Michael, M
Bruns, I
Bölke, E
Zohren, F
Czibere, A
Safaian, N N
Neumann, F
Haas, R
Kobbe, G
Fenk, R
author_sort Michael, M
collection PubMed
description OBJECTIVE: In patients with multiple myeloma, bendamustine monotherapy is effective as 1(st )and 2(nd )line therapy. However, data for patients with advanced multiple myeloma is rare. METHODS: In this retrospective analysis we have identified 39 patients with relapsed or refractory multiple myeloma by means of case research, who have been treated at our institution with bendamustine as salvage therapy. After in median 2 lines of prior therapy (range:1-5) patients received in median 3 (range: 1-10) cycles of bendamustine. Bendamustine dosage was 80-150 mg on day 1+2 of a monthly cycle. Bendamustine was administered as monotherapy in 39% of patients, whereas 61% received concomitant steroids. RESULTS: Toxicity was mild to moderate. Response rates were as follows: 3% vgPR, 33% PR, 18% MR, 26% SD and 20% PD. The median event-free and overall survival were 7 and 17 months, respectively. CONCLUSIONS: In conclusion, in patients with advanced multiple myeloma bendamustine is effective and associated with mild toxicity. Therefore, the role of bendamustine in patients with multiple myeloma should be investigated in further clinical trials.
format Online
Article
Text
id pubmed-3351842
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33518422012-05-16 Bendamustine in patients with relapsed or refractory multiple myeloma Michael, M Bruns, I Bölke, E Zohren, F Czibere, A Safaian, N N Neumann, F Haas, R Kobbe, G Fenk, R Eur J Med Res Research OBJECTIVE: In patients with multiple myeloma, bendamustine monotherapy is effective as 1(st )and 2(nd )line therapy. However, data for patients with advanced multiple myeloma is rare. METHODS: In this retrospective analysis we have identified 39 patients with relapsed or refractory multiple myeloma by means of case research, who have been treated at our institution with bendamustine as salvage therapy. After in median 2 lines of prior therapy (range:1-5) patients received in median 3 (range: 1-10) cycles of bendamustine. Bendamustine dosage was 80-150 mg on day 1+2 of a monthly cycle. Bendamustine was administered as monotherapy in 39% of patients, whereas 61% received concomitant steroids. RESULTS: Toxicity was mild to moderate. Response rates were as follows: 3% vgPR, 33% PR, 18% MR, 26% SD and 20% PD. The median event-free and overall survival were 7 and 17 months, respectively. CONCLUSIONS: In conclusion, in patients with advanced multiple myeloma bendamustine is effective and associated with mild toxicity. Therefore, the role of bendamustine in patients with multiple myeloma should be investigated in further clinical trials. BioMed Central 2010-01-29 /pmc/articles/PMC3351842/ /pubmed/20159666 http://dx.doi.org/10.1186/2047-783X-15-1-13 Text en Copyright ©2010 I. Holzapfel Publishers
spellingShingle Research
Michael, M
Bruns, I
Bölke, E
Zohren, F
Czibere, A
Safaian, N N
Neumann, F
Haas, R
Kobbe, G
Fenk, R
Bendamustine in patients with relapsed or refractory multiple myeloma
title Bendamustine in patients with relapsed or refractory multiple myeloma
title_full Bendamustine in patients with relapsed or refractory multiple myeloma
title_fullStr Bendamustine in patients with relapsed or refractory multiple myeloma
title_full_unstemmed Bendamustine in patients with relapsed or refractory multiple myeloma
title_short Bendamustine in patients with relapsed or refractory multiple myeloma
title_sort bendamustine in patients with relapsed or refractory multiple myeloma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351842/
https://www.ncbi.nlm.nih.gov/pubmed/20159666
http://dx.doi.org/10.1186/2047-783X-15-1-13
work_keys_str_mv AT michaelm bendamustineinpatientswithrelapsedorrefractorymultiplemyeloma
AT brunsi bendamustineinpatientswithrelapsedorrefractorymultiplemyeloma
AT bolkee bendamustineinpatientswithrelapsedorrefractorymultiplemyeloma
AT zohrenf bendamustineinpatientswithrelapsedorrefractorymultiplemyeloma
AT cziberea bendamustineinpatientswithrelapsedorrefractorymultiplemyeloma
AT safaiannn bendamustineinpatientswithrelapsedorrefractorymultiplemyeloma
AT neumannf bendamustineinpatientswithrelapsedorrefractorymultiplemyeloma
AT haasr bendamustineinpatientswithrelapsedorrefractorymultiplemyeloma
AT kobbeg bendamustineinpatientswithrelapsedorrefractorymultiplemyeloma
AT fenkr bendamustineinpatientswithrelapsedorrefractorymultiplemyeloma